Evidence map›Paper›PMID 40822391›Full record

ArticleFrontiers in microbiology2025

Characterization of the antagonistic secondary metabolites of

Na Zhao, Mingjiao Huang, Yang Yang, Ruxia Cai, Jian Peng, Guo Guo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. From Biocontrol to Synthesis: Innovative Progress ofInternational journal of molecular sciences · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Na ZhaoGuizhou Key Laboratory of Microbio and Infectious Disease Prevention & Control, School of Basic Medical Sciences, Guizhou Medical University, Guiyang, China.
Mingjiao HuangGuizhou Key Laboratory of Microbio and Infectious Disease Prevention & Control, School of Basic Medical Sciences, Guizhou Medical University, Guiyang, China.
Yang YangGuizhou Key Laboratory of Microbio and Infectious Disease Prevention & Control, School of Basic Medical Sciences, Guizhou Medical University, Guiyang, China.
Ruxia CaiGuizhou Key Laboratory of Microbio and Infectious Disease Prevention & Control, School of Basic Medical Sciences, Guizhou Medical University, Guiyang, China.
Jian PengGuizhou Key Laboratory of Microbio and Infectious Disease Prevention & Control, School of Basic Medical Sciences, Guizhou Medical University, Guiyang, China.
Guo GuoGuizhou Key Laboratory of Microbio and Infectious Disease Prevention & Control, School of Basic Medical Sciences, Guizhou Medical University, Guiyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Methods: This study used microdilution procedures and growth and bactericidal kinetics studies to investigate the effects of MEZ6 metabolites on MRSA, and reverse-phase high-performance liquid chromatography (HPLC) and mass spectrometry (LC/MC) were used to detect the secondary metabolites of MEZ6. Results and discussion: The results show that MEZ6 secondary metabolites can inhibit MRSA growth, prevent biofilm formation, reduce the expression of virulence genes (

Indexed as

mechanismPaenibacillus polymyxasecondary metabolitesStaphylococcus aureustryptophan-associated fraction

Identifiers

PMID40822391
PMCPMC12350257

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.